A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Phase of Trial: Phase I/II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.
- 25 Aug 2017 Planned initiation date changed from 15 Aug 2017 to 15 Sep 2017.
- 24 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 15 Aug 2017.